Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kuros Biosciences's Enterprise Value is $871.7 Mil.
Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $6.6 Mil. Therefore, Kuros Biosciences's EV-to-EBIT ratio for today is 131.30.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kuros Biosciences's Enterprise Value is $871.7 Mil.
Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $10.8 Mil. Therefore, Kuros Biosciences's EV-to-EBITDA ratio for today is 80.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kuros Biosciences's Enterprise Value is $871.7 Mil.
Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $182.0 Mil. Therefore, Kuros Biosciences's EV-to-Revenue ratio for today is 4.79.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Kuros Biosciences (OTCPK:CSBTF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $6.6 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $10.8 Mil.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $182.0 Mil.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.5 Mil.
Kuros Biosciences's current Enterprise Value is $871.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Enterprise Value Related Terms
Kuros Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Kuros Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kuros Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Enterprise Value of $871.7 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kuros Biosciences and its competitors.
Is Kuros Biosciences' Enterprise Value too high?
Kuros Biosciences' current Enterprise Value is $871.7 Mil. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Enterprise Value compare to ABT and SYK?
Kuros Biosciences' Enterprise Value of $871.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kuros Biosciences and its competitors. Kuros Biosciences's current Enterprise Value is $871.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Enterprise Value is $871.7 Mil. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Enterprise Value is $871.7 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Enterprise Value: $871.7 Mil
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
